Trial Profile
Pilot Evaluation of the Influence of ABT450r, Ombitasvir, Dasabuvir +/- Ribavirin HCV Therapy on Insulin Resistance and Lipid Profile
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Dasabuvir (Primary) ; Ombitasvir/paritaprevir/ritonavir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms 3D
- 09 Aug 2019 Status changed from recruiting to completed.
- 20 Sep 2017 Planned End Date changed from 1 Mar 2017 to 1 Dec 2018.
- 20 Sep 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.